Dasotraline

DB12305InvestigationalSmall molecule

Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and...

Mechanism: Dasotraline has been shown in preclinical studies to be a potent and balanced reuptake inhibitor of serotonin, norepinephrine and dopamine (SNDRI). Serotonin, norepinephrine and dopamine are neurotransmitters associated with depression. There are currently no marketed treatments for depression that inhibit reuptake of all three neurotransmitters.
Curator reviewed
Formula / weight: C₁₆H₁₅Cl₂N · 292.2 g/mol (avg)
Code names: SEP-225289

Resolves to

Compound

UNII4D28EY0L5TCAS675126-05-3ChEMBLCHEMBL3301595PubChem9947999

Structure

InChIKeySRPXSILJHWNFMK-MEDUHNTESA-NSMILESN[C@@H]1CC[C@@H](C2=CC=C(Cl)C(Cl)=C2)C2=CC=CC=C12

Targets

P31645SLC6A4P23975SLC6A2Q01959SLC6A3

What you can answer from here — as of September 16, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dasotraline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account